Want to see GB:VLG full AI Analyst Report?
VLG Stock Chart & Stats
69.50 p
0.00 p(0.00%)
At close: 4:00 PM EDT
69.50 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range52.00 p - 72.00 p
Previous CloseN/A
Volume102.65K
Average Volume (3M)139.02K
Market Cap
£83.97M
Enterprise Value51.47 p
Total Cash (Recent Filing)£34.17M
Total Debt (Recent Filing)£667.00K
Price to Earnings (P/E)16.0
Beta0.26
Next Earnings
Nov 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding120,467,705
10 Day Avg. Volume191,491
30 Day Avg. Volume139,016
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.04
Price to Sales (P/S)2.40
P/FCF Ratio-273.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.07
Revenue Forecast (FY)£42.60M
Bulls Say, Bears Say
Bulls Say
De-risked Balance SheetLeverage fell sharply in 2025, materially strengthening the balance sheet and financial flexibility. A near-elimination of debt reduces solvency risk, lowers interest burden and gives management optionality to fund M&A, product investment or weather downturns without immediate external funding.
Improved 2025 ProfitabilityA return to positive EBIT and a sharp net income uplift demonstrates recovering earnings power and operational leverage. Sustained profitability enhances the firm's ability to internally fund R&D, marketing and international expansion, supporting durable cash generation if maintained.
Diversified OTC Product And Channel FootprintA multi-category OTC portfolio and multi-channel distribution reduce reliance on any single product or market. This diversification supports steady demand for self-care products, enables cross-selling and market expansion, and tends to produce more resilient revenue streams over time.
Bears Say
Revenue Volatility & Margin PressureSwings in revenue combined with gross profit not scaling with sales point to persistent mix or margin weakness. Such structural volatility complicates forecasting, allocates management time to stabilization rather than growth, and can cap sustainable earnings expansion if not resolved.
Inconsistent Cash ConversionA shift to negative operating and free cash flow after prior strong FCF suggests working-capital stress or one-off drains. Unreliable cash conversion limits internal reinvestment capacity, increases dependence on external funding even with low debt, and weakens long-term financial resilience.
Weak Historical Returns On EquityNegative or weak ROE despite a strong equity base implies capital has not been efficiently deployed. Persistent low returns raise concerns about management execution and capital allocation, which can limit long-term shareholder value even with a de-risked balance sheet.
Venture Life News
VLG FAQ
What was Venture Life Group PLC’s price range in the past 12 months?
Venture Life Group PLC lowest share price was 52.00 p and its highest was 72.00 p in the past 12 months.
What is Venture Life Group PLC’s market cap?
Venture Life Group PLC’s market cap is £83.97M.
When is Venture Life Group PLC’s upcoming earnings report date?
Venture Life Group PLC’s upcoming earnings report date is Nov 30, 2026 which is in 113 days.
How were Venture Life Group PLC’s earnings last quarter?
Venture Life Group PLC released its earnings results on Mar 31, 2026. The company reported 0.027 p earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Venture Life Group PLC overvalued?
According to Wall Street analysts Venture Life Group PLC’s price is currently Overvalued.
Does Venture Life Group PLC pay dividends?
Venture Life Group PLC pays a Annually dividend of 0.04 p which represents an annual dividend yield of N/A. See more information on Venture Life Group PLC dividends here
What is Venture Life Group PLC’s EPS estimate?
Venture Life Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Venture Life Group PLC have?
Venture Life Group PLC has 120,467,705 shares outstanding.
What happened to Venture Life Group PLC’s price movement after its last earnings report?
Venture Life Group PLC reported an EPS of 0.027 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.941%.
Which hedge fund is a major shareholder of Venture Life Group PLC?
Currently, no hedge funds are holding shares in GB:VLG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Venture Life Stock Smart Score
Company Description
Venture Life Group PLC
Established in Bracknell, UK, in 2005, Venture Life Group plc is an international developer and marketer of diverse health and personal care items. The company's portfolio spans oral care products, dietary supplements, medical devices, dermo-cosmetics, and topical applications, serving a global market across the United Kingdom, various European countries (including the Netherlands, Germany, Italy, and Switzerland), and China. Operating through its distinct Venture Life Brands and Customer Brands divisions, the company offers a comprehensive array of solutions. These include advanced neurology-focused nutritional supplements such as NeuroAge, NeuroAge Sleep, and NeuroAge NRG, designed to enhance alertness, cognitive abilities, and mental acuity. For hair health, Original Bioscalin addresses hair loss, thinning, and baldness. The Myco Clear range provides antifungal nail solutions, comprising a Fungal Nail Solution for treatment and prevention, and a Fungal Nail Cleanser for foot and hand hygiene. In the realm of oral care, UltraDEX is formulated to combat bad breath, while Dently Dual Action is a mouthwash engineered to effectively remove plaque and bacteria. For anal discomfort, Procto-eze plus offers relief for conditions like haemorrhoids and general irritation. Venture Life also features a dedicated women's healthcare line under the vonalei brand, which includes a refreshing gel for bacterial vaginosis, a vaginal cream for atrophy, a soothing cream-gel for candidiasis (thrush), and an intimate cleansing foam. Its dermo-cosmetic selections encompass the Rosa calma brand's Cleansing Foam, Cleansing Cream, and Serum, alongside the Lubatti Classic and Lubatti Anti-age skincare collections. These skincare lines are meticulously crafted to hydrate, nourish, and recondition the skin, helping to minimize the appearance of lines and wrinkles. The company distributes its extensive product offerings through a broad network that includes international partners, pharmacies, and major grocery retailers.